{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:52Z","timestamp":1776276412699,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune Cell Deconvolution methods utilizing gene expression profiling to quantify immune cells in tissues and blood are an appealing alternative to flow cytometry. Our objective was to investigate the applicability of deconvolution approaches in clinical trial settings to better investigate the mode of action of drugs for autoimmune diseases. Popular deconvolution methods CIBERSORT and xCell were validated using gene expression from the publicly available GSE93777 dataset that has comprehensive matching flow cytometry. As shown in the<jats:italic>online tool<\/jats:italic>,\u2009~\u200950% of signatures show strong correlation (r\u2009&gt;\u20090.5) with the remainder showing moderate correlation, or in a few cases, no correlation. Deconvolution methods were then applied to gene expression data from the phase III CLARITY study (NCT00213135) to evaluate the immune cell profile of relapsing multiple sclerosis patients treated with cladribine tablets. At 96\u00a0weeks after treatment, deconvolution scores showed the following changes vs placebo: na\u00efve, mature, memory CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>T cells, non-class switched, and class switched memory B cells and plasmablasts were significantly reduced, na\u00efve B cells and M2 macrophages were more abundant. Results confirm previously described changes in immune cell composition following cladribine tablets treatment and reveal immune homeostasis of pro- vs anti-inflammatory immune cell subtypes, potentially supporting long-term efficacy.<\/jats:p>","DOI":"10.1038\/s41598-023-34384-5","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T10:02:39Z","timestamp":1684404159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-859X","authenticated-orcid":false,"given":"Irina","family":"Kalatskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8924-8891","authenticated-orcid":false,"given":"Thomas","family":"Leist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Cerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-5284","authenticated-orcid":false,"given":"Ursula","family":"Boschert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-1843","authenticated-orcid":false,"given":"P. Alexander","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"34384_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cpim.40","volume":"120","author":"KM McKinnon","year":"2018","unstructured":"McKinnon, K. M. Flow cytometry: An overview. Curr. Protoc. Immunol. 120, 511\u20135111. https:\/\/doi.org\/10.1002\/cpim.40 (2018).","journal-title":"Curr. Protoc. Immunol."},{"key":"34384_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","volume":"332","author":"SC Bendall","year":"2011","unstructured":"Bendall, S. C. et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332, 687\u2013696. https:\/\/doi.org\/10.1126\/science.1198704 (2011).","journal-title":"Science"},{"key":"34384_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.coi.2013.09.015","volume":"25","author":"SS Shen-Orr","year":"2013","unstructured":"Shen-Orr, S. S. & Gaujoux, R. Computational deconvolution: extracting cell type-specific information from heterogeneous samples. Curr. Opin. Immunol. 25, 571\u2013578. https:\/\/doi.org\/10.1016\/j.coi.2013.09.015 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"34384_CR4","doi-asserted-by":"publisher","first-page":"e6098","DOI":"10.1371\/journal.pone.0006098","volume":"4","author":"AR Abbas","year":"2009","unstructured":"Abbas, A. R., Wolslegel, K., Seshasayee, D., Modrusan, Z. & Clark, H. F. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One 4, e6098. https:\/\/doi.org\/10.1371\/journal.pone.0006098 (2009).","journal-title":"PLoS One"},{"key":"34384_CR5","doi-asserted-by":"publisher","first-page":"e27156","DOI":"10.1371\/journal.pone.0027156","volume":"6","author":"T Gong","year":"2011","unstructured":"Gong, T. et al. Optimal deconvolution of transcriptional profiling data using quadratic programming with application to complex clinical blood samples. PLoS One 6, e27156. https:\/\/doi.org\/10.1371\/journal.pone.0027156 (2011).","journal-title":"PLoS One"},{"key":"34384_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat. Methods"},{"key":"34384_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220. https:\/\/doi.org\/10.1186\/s13059-017-1349-1 (2017).","journal-title":"Genome Biol."},{"key":"34384_CR8","doi-asserted-by":"publisher","first-page":"e000206","DOI":"10.1136\/lupus-2017-000206","volume":"4","author":"S Bandyopadhyay","year":"2017","unstructured":"Bandyopadhyay, S. et al. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci. Med. 4, e000206. https:\/\/doi.org\/10.1136\/lupus-2017-000206 (2017).","journal-title":"Lupus Sci. Med."},{"key":"34384_CR9","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.3390\/cancers12113342","volume":"12","author":"M Oshi","year":"2020","unstructured":"Oshi, M. et al. Plasmacytoid dendritic cell (PDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (CDC). Cancers (Basel) 12, 3342. https:\/\/doi.org\/10.3390\/cancers12113342 (2020).","journal-title":"Cancers (Basel)"},{"key":"34384_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533 (2010).","journal-title":"N. Engl. J. Med."},{"key":"34384_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni, G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics 14, 874\u2013887. https:\/\/doi.org\/10.1007\/s13311-017-0573-4 (2017).","journal-title":"Neurotherapeutics"},{"key":"34384_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","volume":"13","author":"H Wiendl","year":"2017","unstructured":"Wiendl, H. Cladribine\u2014an old newcomer for pulsed immune reconstitution in MS. Nat. Rev. Neurol. 13, 573\u2013574. https:\/\/doi.org\/10.1038\/nrneurol.2017.119 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"34384_CR13","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41467-018-05044-4","volume":"9","author":"S Tasaki","year":"2018","unstructured":"Tasaki, S. et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat. Commun. 9, 2755. https:\/\/doi.org\/10.1038\/s41467-018-05044-4 (2018).","journal-title":"Nat. Commun."},{"key":"34384_CR14","doi-asserted-by":"publisher","first-page":"106478","DOI":"10.1016\/j.intimp.2020.106478","volume":"83","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int. Immunopharmacol. 83, 106478. https:\/\/doi.org\/10.1016\/j.intimp.2020.106478 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"34384_CR15","doi-asserted-by":"publisher","first-page":"103838","DOI":"10.1016\/j.dib.2019.103838","volume":"24","author":"M Zolnoori","year":"2019","unstructured":"Zolnoori, M. et al. The PsyTAR dataset: From patients generated narratives to a corpus of adverse drug events and effectiveness of psychiatric medications. Data Brief 24, 103838. https:\/\/doi.org\/10.1016\/j.dib.2019.103838 (2019).","journal-title":"Data Brief"},{"key":"34384_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/pds.4857","volume":"28","author":"N Gavrielov-Yusim","year":"2019","unstructured":"Gavrielov-Yusim, N. et al. Comparison of text processing methods in social media-based signal detection. Pharmacoepidemiol. Drug Saf. 28, 1309\u20131317. https:\/\/doi.org\/10.1002\/pds.4857 (2019).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"34384_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi, G. et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 29, 168\u2013174. https:\/\/doi.org\/10.1016\/j.msard.2019.01.038 (2019).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"34384_CR18","volume-title":"Straightforward Statistics for the Behavioral Sciences","author":"JD Evans","year":"1996","unstructured":"Evans, J. D. Straightforward Statistics for the Behavioral Sciences (Brooks\/Cole Pub. Co., 1996)."},{"key":"34384_CR19","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1111\/jcmm.15270","volume":"24","author":"M Ju","year":"2020","unstructured":"Ju, M. et al. A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer. J. Cell Mol. Med. 24, 6283\u20136297. https:\/\/doi.org\/10.1111\/jcmm.15270 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"34384_CR20","doi-asserted-by":"publisher","first-page":"e0231003","DOI":"10.1371\/journal.pone.0231003","volume":"15","author":"S Yu","year":"2020","unstructured":"Yu, S. et al. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. PLoS One 15, e0231003. https:\/\/doi.org\/10.1371\/journal.pone.0231003 (2020).","journal-title":"PLoS One"},{"key":"34384_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.33009","volume":"147","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. Int. J. Cancer 147, 542\u2013553. https:\/\/doi.org\/10.1002\/ijc.33009 (2020).","journal-title":"Int. J. Cancer"},{"key":"34384_CR22","doi-asserted-by":"publisher","first-page":"9647072","DOI":"10.1155\/2020\/9647072","volume":"2020","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. The immune cell landscape in different anatomical structures of knee in osteoarthritis: A gene expression-based study. Biomed. Res. Int. 2020, 9647072. https:\/\/doi.org\/10.1155\/2020\/9647072 (2020).","journal-title":"Biomed. Res. Int."},{"key":"34384_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fgene.2020.00382","volume":"11","author":"D Wu","year":"2020","unstructured":"Wu, D. et al. Expression profiling and cell type classification analysis in periodontitis reveal dysregulation of multiple lncRNAs in plasma cells. Front. Genet. 11, 382. https:\/\/doi.org\/10.3389\/fgene.2020.00382 (2020).","journal-title":"Front. Genet."},{"key":"34384_CR24","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1038\/s41598-018-24437-5","volume":"8","author":"N Rohr-Udilova","year":"2018","unstructured":"Rohr-Udilova, N. et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci. Rep. 8, 6220. https:\/\/doi.org\/10.1038\/s41598-018-24437-5 (2018).","journal-title":"Sci. Rep."},{"key":"34384_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/nxi.0000000000000360","volume":"4","author":"D Baker","year":"2017","unstructured":"Baker, D. et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol. Neuroimmunol. Neuroinflamm. 4, 360. https:\/\/doi.org\/10.1212\/nxi.0000000000000360 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"34384_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","volume":"265","author":"B Ceronie","year":"2018","unstructured":"Ceronie, B. et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J. Neurol. 265, 1199\u20131209. https:\/\/doi.org\/10.1007\/s00415-018-8830-y (2018).","journal-title":"J. Neurol."},{"key":"34384_CR27","doi-asserted-by":"crossref","unstructured":"Wiendl, H. et al. Characterization of peripheral immune cell dynamics and repopulation patterns in the first 12 months of cladribine tablets treatment: MAGNIFY-MS. In AAN Virtual Congress (2021).","DOI":"10.1212\/WNL.96.15_supplement.2235"},{"key":"34384_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"D Baker","year":"2019","unstructured":"Baker, D., Pryce, G., Herrod, S. S. & Schmierer, K. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult. Scler. Relat. Disord. 30, 176\u2013186. https:\/\/doi.org\/10.1016\/j.msard.2019.02.018 (2019).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"34384_CR29","doi-asserted-by":"publisher","first-page":"175628641985498","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve, O. et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: An extended analysis of surface markers. Ther. Adv. Neurol. Disord. 12, 1756286419854986. https:\/\/doi.org\/10.1177\/1756286419854986 (2019).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"34384_CR30","doi-asserted-by":"publisher","first-page":"11624","DOI":"10.1038\/ncomms11624","volume":"7","author":"EH Kobayashi","year":"2016","unstructured":"Kobayashi, E. H. et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 7, 11624. https:\/\/doi.org\/10.1038\/ncomms11624 (2016).","journal-title":"Nat. Commun."},{"key":"34384_CR31","first-page":"417","volume":"2","author":"H Zhu","year":"2016","unstructured":"Zhu, H., Jia, Z. & Li, Y. R. Nrf2 signaling in macrophages. React. Oxyg. Species 2, 417\u2013420 (2016).","journal-title":"React. Oxyg. Species"},{"key":"34384_CR32","doi-asserted-by":"publisher","first-page":"107270","DOI":"10.1016\/j.intimp.2020.107270","volume":"91","author":"CBK Mathiesen","year":"2021","unstructured":"Mathiesen, C. B. K. et al. Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro. Int. Immunopharmacol. 91, 107270. https:\/\/doi.org\/10.1016\/j.intimp.2020.107270 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"34384_CR33","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.msard.2021.102859","volume":"50","author":"P Faustino","year":"2021","unstructured":"Faustino, P. et al. Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment. Mult. Scler. Relat. Disord. 50, 102859. https:\/\/doi.org\/10.1016\/j.msard.2021.102859 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"34384_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/wnl.0000000000001302","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos, L. et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 84, 872\u2013879. https:\/\/doi.org\/10.1212\/wnl.0000000000001302 (2015).","journal-title":"Neurology"},{"key":"34384_CR35","doi-asserted-by":"publisher","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","volume":"44","author":"D Baker","year":"2020","unstructured":"Baker, D., Pryce, G., James, L. K., Marta, M. & Schmierer, K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult. Scler. Relat. Disord. 44, 102279. https:\/\/doi.org\/10.1016\/j.msard.2020.102279 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"34384_CR36","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/wnl.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or, A. et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 95, e1999\u2013e2008. https:\/\/doi.org\/10.1212\/wnl.0000000000010380 (2020).","journal-title":"Neurology"},{"key":"34384_CR37","doi-asserted-by":"publisher","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron, A. et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther. Adv. Neurol. Disord. 14, 17562864211012836. https:\/\/doi.org\/10.1177\/17562864211012835 (2021).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"34384_CR38","doi-asserted-by":"publisher","first-page":"102983","DOI":"10.1016\/j.msard.2021.102983","volume":"52","author":"F Buttari","year":"2021","unstructured":"Buttari, F. et al. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult. Scler. Relat. Disord. 52, 102983. https:\/\/doi.org\/10.1016\/j.msard.2021.102983 (2021).","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34384-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34384-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34384-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T07:16:41Z","timestamp":1702451801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34384-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34384"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34384-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Irina Kalatskaya and P. Alexander Rolfe are employees of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA). Gavin Giovannoni has received speaker honoraria and consulting fees from AbbVie, Actelion (Janssen\/J&J), Atara Bio, Almirall, Bayer, Biogen, Celgene (BMS), FivePrime, GlaxoSmithKline, GW Pharma, Ironwood, Merck, Novartis, Merck & Co., Pfizer Inc., Protein Discovery Laboratories, Roche, Sanofi-Genzyme, Teva Pharmaceutical Industries Ltd, UCB, and Vertex Pharmaceuticals; and has received research support unrelated to this study from Biogen, Ironwood, Merck, Novartis, Merck & Co., and Takeda. Thomas Leist has received consultancy fees or clinical research grants from Acorda, Bayer, Biogen, Daiichi, EMD Serono, Inc. (an affiliate of Merck KGaA), Novartis, ONO, Pfizer, and Teva Neuroscience. Joseph Cerra was affiliated at the time of this analysis to EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA). Current affiliation: Northeastern University, Boston, MA, USA. Ursula Boschert is an employee of Ares Trading S.A., Eysins, Switzerland (an affiliate of Merck KGaA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8067"}}